Screener
Nuvectis Pharma, Inc. NVCT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
FAQ
- What is Nuvectis Pharma, Inc.'s cash & equivalents?
- Nuvectis Pharma, Inc. (NVCT) reported cash & equivalents of $25.13M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s cash & equivalents changed year-over-year?
- Nuvectis Pharma, Inc.'s cash & equivalents decreased by 15.9% year-over-year, from $29.86M to $25.13M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s cash & equivalents?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s cash & equivalents has grown at a 53.2% compound annual growth rate (CAGR), from $5.74M to $31.63M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Nuvectis Pharma, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude